Validity of Cost and Utility Results?

Diamantopoulos, A; Sawyer, Laura; Ogale, Sarika; Dejonckheere, F.; Nguyen, CM Bounthavong

doi:10.2165/11633700-000000000-00000

PharmacoEconomics

2012

DOI: 10.2165/11633700-000000000-00000

|View full text |Cite

Validity of Cost and Utility Results?

A Diamantopoulos¹,

Laura Sawyer²,

Sarika Ogale³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2014

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[6][7][8][9] Pharmacoeconomics continues to play a pivotal role in determining cost-benefit analysis. [10][11][12] This field has proven to be instrumental in other aspects of medicine and surgery with regard to new interventions and medications. In the field of allergy, much work has been done with regard to intervention studies in allergic rhinitis (AR) and asthma and cost-effectiveness of medications.…”

mentioning

confidence: 99%

Decision-Making Analysis for Allergen Immunotherapy versus Nasal Steroids in the Treatment of Nasal Steroid–Responsive Allergic Rhinitis

Kennedy

Robinson²,

Christophel

et al. 2014

Am J Rhinol�Allergy

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Decision-Making Analysis for Allergen Immunotherapy versus Nasal Steroids in the Treatment of Nasal Steroid–Responsive Allergic Rhinitis

Kennedy

Robinson²,

Christophel

et al. 2014

Am J Rhinol�Allergy

View full text Add to dashboard Cite

show abstract

The Authorsʼ Reply

et al. 2012

View full text Add to dashboard Cite

Erratum to Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model

Nguyen¹,

Bounthavong²,

Mendes³

et al. 2012

PharmacoEconomics

View full text Add to dashboard Cite

The authors have reported a number of corrections to their analysis following the Letter to the Editor by Diamantopoulos et al. [1] These corrections have not affected the conclusions of the article but have resulted in a number of changes to the cost and utility results presented throughout the text, figures and tables. In addition, a wider range of utility values were tested in the one-way sensitivity analyses as the corrections resulted in a wider variance than previously reported. Please refer to Bounthavong et al.'s reply [2] to Diamantopoulos et al. for a more comprehensive explanation of these errors and to the online corrected version for correct cost and utility results.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Validity of Cost and Utility Results?

Cited by 3 publications

References 2 publications

Decision-Making Analysis for Allergen Immunotherapy versus Nasal Steroids in the Treatment of Nasal Steroid–Responsive Allergic Rhinitis

Decision-Making Analysis for Allergen Immunotherapy versus Nasal Steroids in the Treatment of Nasal Steroid–Responsive Allergic Rhinitis

The Authorsʼ Reply

Erratum to Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model

Contact Info

Product

Resources

About